<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Biomedical Science</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/15FB7F7C-BB0A-4883-BF0A-B5C623D5D05B"><gtr:id>15FB7F7C-BB0A-4883-BF0A-B5C623D5D05B</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:surname>Smythe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DFE52416-BCD8-419D-B517-5A6BD86FDB8A"><gtr:id>DFE52416-BCD8-419D-B517-5A6BD86FDB8A</gtr:id><gtr:firstName>Andrew James</gtr:firstName><gtr:surname>Grierson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BE65575B-A261-4126-8A9C-086CA5A6E1DD"><gtr:id>BE65575B-A261-4126-8A9C-086CA5A6E1DD</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Ingham</gtr:surname><gtr:orcidId>0000-0001-8224-9958</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0401352"><gtr:id>0F9917A6-7B2C-4B07-B703-0A5EC391B94D</gtr:id><gtr:title>Pathfinder: Neurotrophic signalling in Motor Neurone Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401352</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>161842</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MND care-givers conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>66FA8EAD-FB67-4F36-AF68-99DE3B3D8DF0</gtr:id><gtr:impact>Invited to give scientific presentation to a lay audience at a meeting

discussions with patients and care givers feedback (2 way)</gtr:impact><gtr:outcomeId>A26CD1B4438</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>39C29136-311A-49CB-80BC-A93B6EF77738</gtr:id><gtr:outcomeId>bQBKB3y8rm10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>zebrafish bearing ENU-induced mutations in the alsin gene</gtr:description><gtr:id>F08329E3-0EF0-4DA8-83AF-075168F629EC</gtr:id><gtr:impact>Ongoing research using these fish</gtr:impact><gtr:outcomeId>4B25D468670</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>genetically modified zebrafish</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>493A42DA-B3CD-402E-8C06-798C6F75C0C9</gtr:id><gtr:title>New pedigrees and novel mutation expand the phenotype of REEP1-associated hereditary spastic paraplegia (HSP).</gtr:title><gtr:parentPublicationTitle>Neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74c1ce165d5b40a47e512bbc12f51fc7"><gtr:id>74c1ce165d5b40a47e512bbc12f51fc7</gtr:id><gtr:otherNames>Hewamadduma C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1364-6745</gtr:issn><gtr:outcomeId>C13E3F0D628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0BC0ACA-3492-48DF-8D38-FC93548493A1</gtr:id><gtr:title>Role of axonal transport in neurodegenerative diseases.</gtr:title><gtr:parentPublicationTitle>Annual review of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19d0493aca288feb1c7b928115cc28a"><gtr:id>a19d0493aca288feb1c7b928115cc28a</gtr:id><gtr:otherNames>De Vos KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0147-006X</gtr:issn><gtr:outcomeId>AA557F0346F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C1DE335-814A-43BD-80B9-D6AD1011F33E</gtr:id><gtr:title>Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19d0493aca288feb1c7b928115cc28a"><gtr:id>a19d0493aca288feb1c7b928115cc28a</gtr:id><gtr:otherNames>De Vos KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>4B4259BAE83</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA9F6300-9DA2-40C8-A695-126EA5B33B6E</gtr:id><gtr:title>Direct evidence for axonal transport defects in a novel mouse model of mutant spastin-induced hereditary spastic paraplegia (HSP) and human HSP patients.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/514ce09c22d26da59e5c0c025e41fb21"><gtr:id>514ce09c22d26da59e5c0c025e41fb21</gtr:id><gtr:otherNames>Kasher PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>531182A8879</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401352</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>